WO2015093924A1 - Véhicule pour l'administration de composés pharmaceutiques - Google Patents

Véhicule pour l'administration de composés pharmaceutiques Download PDF

Info

Publication number
WO2015093924A1
WO2015093924A1 PCT/MX2013/000188 MX2013000188W WO2015093924A1 WO 2015093924 A1 WO2015093924 A1 WO 2015093924A1 MX 2013000188 W MX2013000188 W MX 2013000188W WO 2015093924 A1 WO2015093924 A1 WO 2015093924A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
polyvinyl
vehicle
active substance
administration
Prior art date
Application number
PCT/MX2013/000188
Other languages
English (en)
Spanish (es)
Inventor
José de Jesús MONCADA ZUNO
Original Assignee
CASTRO ALDRETE, Jorge Issac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CASTRO ALDRETE, Jorge Issac filed Critical CASTRO ALDRETE, Jorge Issac
Priority to PCT/MX2013/000188 priority Critical patent/WO2015093924A1/fr
Publication of WO2015093924A1 publication Critical patent/WO2015093924A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • intramuscular administration develops an intense local reaction with hair loss. After subcutaneous administration, the area adjacent to the inoculation point may edematize in a mild and transient manner.
  • a medicine is basically composed of:
  • excipient which is the vehicle to which the active substance is incorporated to be able to administer it, since in most cases the amount of active ingredient that must be supplied is so small that we could not even take it.
  • excipients for pharmaceutical raw materials for the production of dosage forms can be solid, liquid and semi-solid. Each having its own advantages and disadvantages. So far, polyvinyl has been used in various industrial applications without being used for a pharmaceutical formulation, having the advantage that it is stable, non-toxic and capable of containing the active substances and releasing them to achieve high concentrations, thereby the animal subject to which it was administered benefits.
  • the capsules do not have any more advantages when compared with the tablets as they integrate more rapidly in the presence of gastric fluids. Perhaps the only advantage is that there may be a variable absorption time. They are administered as capsules. There are some advantages, which are: Protect the drug from external agents, but not from moisture. They have a high physical resistance, it is enhanced if it is conditioned in a blister. Masks unpleasant organoleptic characteristics. Rigid capsules have a simple composition and elaboration. With the soft capsules a great accuracy in the dose is achieved. They allow controlled release systems. They have bioavailability characteristics.
  • the extended-release capsules are a presentation in which the drug particles are covered by substances such as resins that control the release of the drug for a longer time, which allows more time to be spaced between doses.
  • This group includes systems designed to release the drug in a delayed manner, which, without prolonging the therapeutic effect, allow the modification of the time or place where the release will occur.
  • enteric cover systems that have the purpose of saving the contact of the active substance with gastric juices, well to prevent its inactivation or to prevent its gastrolesivity (example: microencapsulated aspirin).
  • lipid, hydrophilic or insoluble polymers that allow the diffusion or release of the active ingredient in a more uniform and prolonged manner.
  • An example of this is tamsulosin matrix tablets. This technology is also in the transdermal route of administration with fentanyl matrix patches. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention is carried out by grinding polyvinyl solid material to reach particles less than 0.01 millimeter thick.
  • This material must be free of any contamination before entering the process, which can be done with any conventional process, which will not be included in this invention.
  • the material must be allowed to dry for two hours before being used. Subsequently it is introduced into an alcohol solution to free it from any impurity. Once the material is clean it can be included in a clean container where the pharmaceutical substance to be administered is preserved, it should be mentioned that said substance must be in a liquid state and not contain lumps.
  • the formula object of this invention has two main variants that can be consumed by water or injectable for these animals.
  • the present formula has chemical action that allows a better administration of the active substance achieved through the combination of a polyvinyl with the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une formule qui utilise des particules de polyvinyle comme véhicule d'approvisionnement en médicaments. Cette invention comprend deux variants principaux qui peuvent être consommés avec de l'eau ou injectés pour ces animaux. La présente formule a une action chimique qui permet une meilleure administration de la substance active grâce à sa combinaison avec un polyvinyle. Ce polyvinyle peut agir comme véhicule préféré de l'invention pour obtenir les meilleurs résultats.
PCT/MX2013/000188 2013-12-19 2013-12-19 Véhicule pour l'administration de composés pharmaceutiques WO2015093924A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000188 WO2015093924A1 (fr) 2013-12-19 2013-12-19 Véhicule pour l'administration de composés pharmaceutiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000188 WO2015093924A1 (fr) 2013-12-19 2013-12-19 Véhicule pour l'administration de composés pharmaceutiques

Publications (1)

Publication Number Publication Date
WO2015093924A1 true WO2015093924A1 (fr) 2015-06-25

Family

ID=53403166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2013/000188 WO2015093924A1 (fr) 2013-12-19 2013-12-19 Véhicule pour l'administration de composés pharmaceutiques

Country Status (1)

Country Link
WO (1) WO2015093924A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125725A1 (fr) * 1983-05-09 1984-11-21 Gist-Brocades N.V. Solutions d'oxytétracycline
US6075107A (en) * 1997-05-07 2000-06-13 Basf Aktiengesellschaft Use of copolymers of N-vinylprrolidone in preparations of water-insoluble substances
WO2002012241A1 (fr) * 2000-08-08 2002-02-14 Cristália Produtos Químicos e Farmacêuticos Ltda. Composes sous forme de promedicaments homodimeriques, heterodimeriques et/ou homo et heteromultimeriques; procedes permettant d'obtenir ces promedicaments ainsi que leurs sels pharmaceutiquement acceptables; utilisation de ces composes dans le traitement du dysfonctionnement et/ou des maladies induits par la phosphodiestera
US20030022828A1 (en) * 1998-10-16 2003-01-30 Rama Akella Povidone-containing carriers for polypeptide growth factors
WO2003072112A1 (fr) * 2002-02-28 2003-09-04 Norbrook Laboratories Limited Composition antiparasitaire injectable a action prolongee
FR2921541A1 (fr) * 2007-10-02 2009-04-03 Ab7 Ind Sa Dispositif repulsif contre les parasites des animaux domestiques
US20130267472A1 (en) * 2012-03-22 2013-10-10 Laboratoires Thea Aqueous ophthalmic solution based on cyclosporin
FR2991173A1 (fr) * 2012-06-04 2013-12-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125725A1 (fr) * 1983-05-09 1984-11-21 Gist-Brocades N.V. Solutions d'oxytétracycline
US6075107A (en) * 1997-05-07 2000-06-13 Basf Aktiengesellschaft Use of copolymers of N-vinylprrolidone in preparations of water-insoluble substances
US20030022828A1 (en) * 1998-10-16 2003-01-30 Rama Akella Povidone-containing carriers for polypeptide growth factors
WO2002012241A1 (fr) * 2000-08-08 2002-02-14 Cristália Produtos Químicos e Farmacêuticos Ltda. Composes sous forme de promedicaments homodimeriques, heterodimeriques et/ou homo et heteromultimeriques; procedes permettant d'obtenir ces promedicaments ainsi que leurs sels pharmaceutiquement acceptables; utilisation de ces composes dans le traitement du dysfonctionnement et/ou des maladies induits par la phosphodiestera
WO2003072112A1 (fr) * 2002-02-28 2003-09-04 Norbrook Laboratories Limited Composition antiparasitaire injectable a action prolongee
FR2921541A1 (fr) * 2007-10-02 2009-04-03 Ab7 Ind Sa Dispositif repulsif contre les parasites des animaux domestiques
US20130267472A1 (en) * 2012-03-22 2013-10-10 Laboratoires Thea Aqueous ophthalmic solution based on cyclosporin
FR2991173A1 (fr) * 2012-06-04 2013-12-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide

Similar Documents

Publication Publication Date Title
Nagar et al. Orally disintegrating tablets: formulation, preparation techniques and evaluation
ES2210280T3 (es) Moldeado comprimido de solubilidad intra-oral y su procedimiento de produccion.
Gauri et al. Fast dissolving drug delivery and its technologies.
ES2620672T3 (es) Comprimidos de doble capa que comprenden oxicodona y prometazina
ES2217410T3 (es) Forma de dosificacion oral de rapida desintegracion.
Hooda et al. A review on oral mucosal drug delivery system
ES2325339T3 (es) Capsulas blandas que comprenden hidrocloruro de palonosetron que tienen una estabilidad y una biodisponibilidad mejoradas.
Boateng Drug delivery innovations to address global health challenges for pediatric and geriatric populations (through improvements in patient compliance)
ES2794374T3 (es) Preparación líquida anhidra de melatonina
US20140364513A1 (en) Highly robust fast-disintegrating tablet and process for manufacturing the same
BRPI0620403B1 (pt) filme bioadesivo, unidade de dosagem, método de fabricação de um filme bioadesivo, e, uso de uma composição
BRPI0711997A2 (pt) preparaÇço farmacÊutica, uso de uma forma de dosagem, uso de uma combinaÇço de agentes ativos, mÉtodo para o tratamento terapÊutico de um indivÍduo e mÉtodo para a produÇço de uma forma de dosagem no formato de uma folha
EP2453743A1 (fr) Compositions de n-acétyl cystéine et procédés pour améliorer l'efficacité thérapeutique de l'acétaminophène
ES2334777T3 (es) Formulas farmaceuticas para hormonas tiroideas y procedimientos para su obtencion.
ES2611019T3 (es) Tratamiento de las quemaduras solares usando analgésicos y antihistamínicos
WO2015093924A1 (fr) Véhicule pour l'administration de composés pharmaceutiques
ES2336578T3 (es) Uso de pilocarpina para el tratamiento de hiposialismos.
Naman et al. Formulation design and pharmaceutical considerations for paediatric patients: current status and future dimensions
ES2215307T3 (es) Composiciones con accion sinergica para combatir selectivamente tejidos tumorales.
CA2623306C (fr) Excipient oral pour produits pharmaceutiques systematiques
RoshanRai et al. Fast dissolving tablets: A novel approch to drug delivery–A Review
Kamal et al. Approaches to overcome NSAID induced ulceration in arthritic pain management: perspectives and prospects
ES2446363T3 (es) Composición farmacéutica oral de nifedipino
Shalini et al. A laconic overview on fast dissolving sublingual films as propitious dosage form
Gawai et al. formualtion and development of mucoadhesive sustained release buccal tablets and patches of 5-fluorouracil using different polymers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13899833

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13899833

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 23-11-2016)